SAN DIEGO--- Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development

Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Douglas B. Muchmore, MD, has joined the company as Vice President, Endocrinology Clinical Development. "I am thrilled to welcome an individual of Dr. Muchmore's high caliber and achievement to the Halozyme leadership team. He is a widely... [read full story]                    

Add Comment
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies